Navigation Links
Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
Date:7/16/2009

ZURICH, July 16 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients. For Axentis Pharma AG of Zurich, Switzerland, both designations affirm the therapeutic potential of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin).

Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted a second orphan drug designation to its lead product candidate Fluidosomes(TM)-tobramycin. This drug is a liposomal formulation of tobramycin and an innovative treatment for infections of the respiratory tract in patients with cystic fibrosis. Only three months ago, the FDA granted Fluidosomes(TM)-tobramycin orphan drug designation for the treatment of pulmonary infections caused by Pseudomonas aeruginosa. The newly granted second designation relates to pulmonary infections caused by Burkholderia cepacia (B. cepacia) pathogens.

Despite stringent infection control practices, B. cepacia infections still occur in cystic fibrosis patients and can lead to fatal sepsis. The cell envelopes of these especially virulent bacteria are impermeable to most antibiotics, which makes them particularly difficult to treat. Due to its unique mode of action, which allows the antibiotics to penetrate into the bacteria, Fluidosomes(TM)-tobramycin could become a particularly effective treatment for B. cepacia infections.

Prof. Dr. Miguel A Valvano, MD, Medical Advisor to Axentis Pharma, comments on the development: "Burkholderia cepacia is almost always mu
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014   , 2014 Second Quarter ... prior year , Overall organic growth was 4% for same ... products; Bausch + Lomb grew 12% , 2014 Second ... 43% , 2014 Second Quarter GAAP Operating Cash Flow ... , Highlights of the Second Quarter , Launched 17 new ...
(Date:7/31/2014)... PARK, N.C. , July 31, 2014 ... Miami facilities to meet the clinical trial ... .  The newly expanded facility will continue to ... consolidation of shipments to and from the region, and ... its newest location, Marken will combine its office and ...
(Date:7/31/2014)... , July 31, 2014 Auxilium ... a specialty biopharmaceutical company, today announced that the ... payment from its partner Asahi Kasei Pharma Corporation ... the successful submission of a regulatory application to ... for XIAFLEX ® (collagenase clostridium histolyticum) for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 26Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 27Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 28Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 29Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 30Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 31Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 32Marken Expands Miami Regional Logistics Center 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4
... , BUDAPEST, Hungary , ... Pfizer Globally Licenses ChemAxon,s Platform For Markush Structure,Searching And Enumeration ... of cheminformatics software for the life,sciences industry has entered into ... functionality for global,development and deployment within Pfizer,s global R&D facilities. ...
... , , , ... The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) ... sclerosis (MS). In clinical trials, patients treated with Ampyra had ... (placebo). This is the first drug approved for this use. ...
Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2
(Date:7/31/2014)... Some pain relief medications can be as addictive as heroin ... 46 people in the U.S. die from legal pain pills ... to an emergency room because of opioid complications. Consumer ... prescription and over-the-counter painkillers and is calling on the U.S. ... these drugs safer. , The full report, “Deadly Pain Pills” ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 ... IT solutions firm based in New York City, has ... infrastructure for the midtown Manhattan headquarters of a large ... corporate and investment banking. , Chico Ramnarayan, Chief Executive ... our client is an opportunity for us to further ...
(Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
(Date:7/31/2014)... 2014 Staying happy in a relationship and ... Men and women get sucked into the logistical ruts they ... taxi services to kids. , That’s why Couples in ... + Fun Ways to Reignite the Spark in Your Marriage ... “This is a much better path to happiness, and a ...
(Date:7/31/2014)... 2014 Loffler Companies, the leading business ... recognized by Microsoft as a Microsoft Community Connections Partner ... on July 14, 2014. , The Microsoft U.S. ... that deliver cloud-based IT services and solutions to small ... an U.S. SMB Champions Club member, Loffler has established ...
Breaking Medicine News(10 mins):Health News:Consumer Reports Warns Against the Risks of Prescription and Over-The-Counter Painkillers 2Health News:Consumer Reports Warns Against the Risks of Prescription and Over-The-Counter Painkillers 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3
... not to board a transatlantic flight with a potentially deadly ... and two Czechs who flew with him, media said ... scare two months ago when he flew to Montreal via ... Disease Control (CDC) had said he was infected with a ...
... operation for a rare birth defect has more than one share ... illegal immigrants in the U.S, have also been granted a ... daughter. ,Hazelle Roas little-known genetic abnormality left her with ... kept her in the hospital most of her life. According ...
... tattoo done of their lover's initials due to fear of ... - researchers have discovered a technique, where the cryptic body ... choice. ,The new method is called micro-encapsulation, where ... that are as tiny as pins, can bear a molecule ...
... of foods like white rice, pasta and bread, which ... macular degeneration (AMD). ,However, whole-wheat versions of ... have a low-glycemic-index. These foods are often considered higher ... and less dramatic rise and fall of blood sugar. ...
... turned nasty for a group of around ten ... , A Srilankan group of students who visited ... picnic organized by the Punqudutivu Students Association of Sri Lanka ... and abdominal cramps.,Toronto Public Health on Thursday confirmed six cases ...
... cash in on the Dutch laws. ,The former American ... cookie while touring in the Netherlands. ,"It was ... legal here. I don't ever do anything illegal here, People ... 25-year-old singer said that the cookie was an experiment and ...
Cached Medicine News:Health News:US TB Traveler Sued Over 'reckless and Selfish Behavior' 2Health News:Too Much White Rice, Pasta and Bread may Increase Chances of AMD 2Health News:Too Much White Rice, Pasta and Bread may Increase Chances of AMD 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: